Presentation is loading. Please wait.

Presentation is loading. Please wait.

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Published byMarie-Anne Carignan Modified over 6 years ago

Similar presentations

Presentation on theme: "Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K"— Presentation transcript:

1 Variation in Experts’ Beliefs about Lung Cancer Growth, Progression, and Prognosis 
Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K. Gould, MD, MS  Journal of Thoracic Oncology  Volume 3, Issue 4, Pages (April 2008) DOI: /JTO.0b013e b Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Expert Panel Agreement with Assumptions, Round 2. Expert agreement with assumptions about tumor growth, disease progression and survival in patients with NSCLC, after the second survey round. Responses of “Agree” and “Strongly Agree” were combined, as were responses of “Disagree” and “Strongly Disagree.” One expert did not provide a response to the final assumption. NSCLC, non-small cell lung cancer; TVDT, tumor volume doubling time. Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e b) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

3 Journal of Thoracic Oncology 2008 3, 422-426DOI: (10. 1097/JTO
Journal of Thoracic Oncology 2008 3, DOI: ( /JTO.0b013e b) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K"

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
PUBLISH ONLY Journal of Thoracic Oncology

PUBLISH ONLY Journal of Thoracic Oncology
Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers 

Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers 
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.
Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D
Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy 
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.
Frank Detterbeck, MD  Journal of Thoracic Oncology 

Frank Detterbeck, MD  Journal of Thoracic Oncology 

Similar presentations

Ads by Google